MedKoo Cat#: 525368 | Name: NNC63-0532
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NNC63-0532 is a potent and selective non-peptide agonist of the NOP receptors.

Chemical Structure

NNC63-0532
NNC63-0532
CAS#250685-44-0

Theoretical Analysis

MedKoo Cat#: 525368

Name: NNC63-0532

CAS#: 250685-44-0

Chemical Formula: C27H29N3O3

Exact Mass: 443.2209

Molecular Weight: 443.55

Elemental Analysis: C, 73.11; H, 6.59; N, 9.47; O, 10.82

Price and Availability

Size Price Availability Quantity
10mg USD 415.00 2 Weeks
50mg USD 1,415.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
NNC63-0532
IUPAC/Chemical Name
8-(1-Naphthalenylmethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-3-acetic acid, methyl ester
InChi Key
AQMPIDSGLFVVPL-UHFFFAOYSA-N
InChi Code
InChI=1S/C27H29N3O3/c1-33-25(31)19-29-20-30(23-11-3-2-4-12-23)27(26(29)32)14-16-28(17-15-27)18-22-10-7-9-21-8-5-6-13-24(21)22/h2-13H,14-20H2,1H3
SMILES Code
O=C(OC)CN1CN(C2=CC=CC=C2)C3(CCN(CC4=C5C=CC=CC5=CC=C4)CC3)C1=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
NNC63-0532 is a potent and selective non-peptide agonist of the NOP receptors.
In vitro activity:
NNC 63-0532 showed only moderate affinity for the following receptors (K:(i) values in parentheses): mu-opioid (140 nM), kappa-opioid (405 nM), dopamine D(2S) (209 nM), dopamine D(3) (133 nM) and dopamine D(4.4) (107 nM) out of 75 different receptors, ion-channels and transporters. In functional assays, NNC 63-0532 was shown to be an agonist at ORL1 (EC(50)=305 nM), a much weaker agonist at the mu-opioid receptor (EC(50)>10 microM) and an antagonist or weak partial agonist at dopamine D(2S) (IC(50)=2830 nM). Reference: Br J Pharmacol. 2000 Nov;131(5):903-8. https://pubmed.ncbi.nlm.nih.gov/11053209/
In vivo activity:
TBD
Solvent mg/mL mM
Solubility
DMSO 22.2 50.00
Ethanol 2.2 5.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 443.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
Thomsen C, Hohlweg R. (8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triaza-spiro[4. 5]dec-3-yl)-acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist. Br J Pharmacol. 2000 Nov;131(5):903-8. doi: 10.1038/sj.bjp.0703661. PMID: 11053209; PMCID: PMC1572417.
In vitro protocol:
Thomsen C, Hohlweg R. (8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triaza-spiro[4. 5]dec-3-yl)-acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist. Br J Pharmacol. 2000 Nov;131(5):903-8. doi: 10.1038/sj.bjp.0703661. PMID: 11053209; PMCID: PMC1572417.
In vivo protocol:
TBD